150 related articles for article (PubMed ID: 35871485)
21. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
22. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
Bennett R; Thompson E; Tam C
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
24. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
Blombery P; Thompson ER; Nguyen T; Birkinshaw RW; Gong JN; Chen X; McBean M; Thijssen R; Conway T; Anderson MA; Seymour JF; Westerman DA; Czabotar PE; Huang DCS; Roberts AW
Blood; 2020 Mar; 135(10):773-777. PubMed ID: 31951646
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax targets BCL2 in chronic lymphocytic leukaemia.
Brower V
Lancet Oncol; 2016 Jan; 17(1):e11. PubMed ID: 26687593
[No Abstract] [Full Text] [Related]
27. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
Tang X; Zou W; Peng P; Bai Y
Clin Exp Med; 2022 May; 22(2):161-171. PubMed ID: 34224006
[TBL] [Abstract][Full Text] [Related]
29. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
[No Abstract] [Full Text] [Related]
30. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
31. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A; Mauro FR; Scarfò L; Gentile M; Farina L; Reda G; Ferrarini I; Proietti G; Derenzini E; Cibien F; Vitale C; Sanna A; Pietrasanta D; Marchetti M; Murru R; Rigolin GM; Sportoletti P; Trimarco V; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Zatta I; Laurenti L; Molica S; Coscia M; Ghia P; Foà R; Cuneo A; Trentin L
Am J Hematol; 2023 Sep; 98(9):E237-E240. PubMed ID: 37382471
[No Abstract] [Full Text] [Related]
32. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
33. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax in the treatment of chronic lymphocytic leukemia.
Korycka-Wolowiec A; Wolowiec D; Kubiak-Mlonka A; Robak T
Expert Opin Drug Metab Toxicol; 2019 May; 15(5):353-366. PubMed ID: 30969139
[TBL] [Abstract][Full Text] [Related]
36. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.
Birkinshaw RW; Gong JN; Luo CS; Lio D; White CA; Anderson MA; Blombery P; Lessene G; Majewski IJ; Thijssen R; Roberts AW; Huang DCS; Colman PM; Czabotar PE
Nat Commun; 2019 Jun; 10(1):2385. PubMed ID: 31160589
[TBL] [Abstract][Full Text] [Related]
37. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Cramer P; von Tresckow J; Bahlo J; Robrecht S; Langerbeins P; Al-Sawaf O; Engelke A; Fink AM; Fischer K; Tausch E; Seiler T; Fischer von Weikersthal L; Hebart H; Kreuzer KA; Böttcher S; Ritgen M; Kneba M; Wendtner CM; Stilgenbauer S; Eichhorst B; Hallek M
Lancet Oncol; 2018 Sep; 19(9):1215-1228. PubMed ID: 30115596
[TBL] [Abstract][Full Text] [Related]
38. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
39. Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far.
Held L; Siu C; Shadman M
Expert Opin Pharmacother; 2021 Apr; 22(6):655-665. PubMed ID: 33645381
[TBL] [Abstract][Full Text] [Related]
40. Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.
Siddiqui MT; Price A; Ferrajoli A; Borthakur G
Leuk Res Rep; 2021; 16():100266. PubMed ID: 34692401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
